Prostate Cell News Volume 12.05 | Feb 12 2021

    0
    34






    2021-02-11 | PCN 12.05


    Prostate Cell News by STEMCELL Technologies
    Vol. 12.05 – 12 February, 2021
    TOP STORY

    Emergence of Enzalutamide Resistance in Prostate Cancer Is Associated with BCL-2 and IKKB Dependencies

    Scientists identified BCL-2 and IKKB dependencies in clinically relevant enzalutamide-resistant prostate cancer cells in vitro and in vivo.
    [Clinical Cancer Research]

    Abstract

    Enter a contest to win a personalized lab coat by subscribing to Organoid News!
    PUBLICATIONSRanked by the impact factor of the journal

    ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer

    Potent and direct androgen receptor-mediated induction of ELOVL fatty acid elongase 5 (ELOVL5), an enzyme that catalyzes fatty acid elongation, was demonstrated in prostate cancer cells, xenografts, and clinical tumors.
    [Cancer Research]

    Abstract

    Long-Chain Fatty Acyl-CoA Synthetase 1 Promotes Prostate Cancer Progression by Elevation of Lipogenesis and Fatty Acid Beta-oxidation

    A systematical analysis of long-chain fatty acyl-CoA synthetases (ACSLs) levels and the amount of fatty acyl-CoAs illustrated that ACSL1 were significantly associated with the levels of a broad spectrum of fatty acyl-CoAs, and were elevated in human prostate tumors.
    [Oncogene]

    Abstract

    USP16 Regulates Castration-Resistant Prostate Cancer Cell Proliferation by Deubiquitinating and Stablizing C-Myc

    Functional analyses identified USP16, known as a deubiquitinase, was strongly correlated with the c-Myc gene signature. Depletion of USP16 was shown to significantly suppress the growth of prostate cancer cells both in vitro and in vivo.
    [Journal of Experimental & Clinical Cancer Research]

    Full Article

    Metformin and Androgen Receptor-Axis-Targeted (ARAT) Agents Induce Two PARP-1-Dependent Cell Death Pathways in Androgen-Sensitive Human Prostate Cancer Cells

    Researchers explored whether the anti-prostate cancer activity of the ARATs abiraterone and enzalutamide was enhanced by metformin.
    [Cancers]

    Full Article

    SWATH-MS Based Proteomic Profiling of Prostate Cancer Cells Reveals Adaptive Molecular Mechanisms in Response to Anti-Androgen Therapy

    Scientists interrogated both proteomics and transcriptomic alterations stimulated in the AR antagonist/anti-androgen treated androgen-dependent cell model in comparison with androgen-independent/castration-resistant cell model.
    [Cancers]

    Full ArticleGraphical Abstract

    V-ATPase Inhibition Decreases Mutant Androgen Receptor Activity in Castrate-Resistant Prostate Cancer

    Investigators indicated that V-ATPase dysregulation was directly linked to both hormone responsive and castrate-resistant prostate cancer via impact on androgen receptor function.
    [Molecular Cancer Therapeutics]

    Abstract

    ZRSR2 Overexpression Is a Frequent and Early Event in Castration-Resistant Prostate Cancer Development

    Scientists identified potential early driver genes responsible for castration-resistant prostate cancer development.
    [Prostate Cancer and Prostatic Diseases]

    Abstract

    66Ga-PET-Imaging of GRPR-Expression in Prostate Cancer: Production and Characterization of [66Ga]Ga-NOTA-PEG2-RM26

    Researchers produced gallium-66 suitable for radiolabeling, and investigated the imaging properties of gallium-66 labeled gastrin-releasing peptide receptor (GRPR)-antagonist NOTA-PEG2-RM26 for later-time point PET-imaging of GRPR expression. In vitro, [66Ga]-NOTA-PEG2-RM26 was characterized in GRPR-expressing PC-3 prostate cancer cells.
    [Scientific Reports]

    Full Article

    Connect with us via LiveChat to ask your scientific support questions
    REVIEWS

    Prostate Cancer

    The authors aim to improve prostate cancer detection, management and outcomes, including understanding the fundamental biology at all stages of the disease.
    [Nature Reviews Disease Primers]

    Full Article

    Clinical Considerations for the Management of Androgen Indifferent Prostate Cancer

    Investigators summarize the current knowledge on androgen indifferent prostate cancer (AIPC) variants, including the current understanding of the clinical, morphologic, and molecular features as well as current therapeutic approaches. They also explore emerging therapies and biomarkers aimed at improving outcomes for men with AIPC.
    [Prostate Cancer and Prostatic Diseases]

    Abstract

    INDUSTRY AND POLICY NEWS

    Janssen Announces Treatment with ERLEADA® (Apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer

    The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the final analysis of the Phase III TITAN study, which demonstrated the continued statistically significant benefit of the addition of apalutamide to androgen deprivation therapy (ADT) in overall survival in patients with metastatic castration-sensitive prostate cancer, regardless of extent of disease, when compared to placebo plus ADT.
    [Janssen Pharmaceutical Companies of Johnson & Johnson]

    Press Release

    FEATURED EVENT

    The American Association for Cancer Research (AACR) Annual Meeting 2021: Week 2

    May 17 – 21, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Fellow – Prostate Cancer Biology

    The University of Texas MD Anderson Cancer Center – Houston, Texas, United States

    Postdoctoral Fellow – Prostate Cancer Treatment

    The University of British Columbia – Vancouver, British Columbia, Canada

    Postdoctoral Research Fellow – Autophagy in Prostate Cancer

    Oslo University Hospital – Oslo, Norway

    Bioinformatician – Prostate Cancer Genomics Research

    Vall D’Hebron Institute of Oncology – Barcelona, Spain

    Postdoctoral Fellow – Tumor Biology and Therapeutic Applications

    Harvard Medical School – Boston, Massachusetts, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Prostate Cell News Twitter